Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo

A New Preclinical 3-Dimensional Agarose Colony Formation Assay

(2014) Yoshinori Kajiwara et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells

(2014) Erina Vlashi et al.   Translational Oncology

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

(2012) Jeffrey L. Wolf et al.   LEUKEMIA & LYMPHOMA

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

(2011) B. C. Potts et al.   CURRENT CANCER DRUG TARGETS

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

(2011) Daniel R. Premkumar et al.   MOLECULAR CARCINOGENESIS

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

(2011) B. B. Friday et al.   NEURO-ONCOLOGY

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

(2010) Ajita V. Singh et al.   BRITISH JOURNAL OF HAEMATOLOGY

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

(2009) C. P. Miller et al.   BLOOD

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

(2009) E. M. Ocio et al.   HAEMATOLOGICA

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

(2009) G Perrone et al.   LEUKEMIA

Characterization of Cytoplasmic Caspase-2 Activation by Induced Proximity

(2009) Lisa Bouchier-Hayes et al.   MOLECULAR CELL

A tumor suppressor function for caspase-2

(2009) L. H. Ho et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies

(2008) Sherry Wolf et al.   EUROPEAN JOURNAL OF CANCER